HealthInvestor Asia Summit 2018
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: Healthcare m&a to jump 80% in 2018

After a subdued 2017, healthcare mergers & acquisitions are expected to jump more than 80% this year in Asia Pacific to US$55.1 billion, according to global law firm Baker McKenzie.

Uncertainty in the wake of Brexit, the US presidential election and pending US tax reform cooled healthcare m&a activity in 2017. In 2018, however, Baker McKenzie is forecasting that current buoyant market conditions and clarity about the US’s new corporate tax rate will lead to a rebound in deal activity, causing global healthcare m&a to rise to US$418 billion, up 50% from US$277 billion last year.

In Asia Pacific, a major driver of m&a transactions continues to be big pharma buying manufacturing sites in lower cost jurisdictions like Vietnam and India. Pharma companies are also acquiring local companies for their distribution networks in emerging markets like China to gain access to the growing middle class that now has disposable income to spend on healthcare.

The total value of IPOs in the healthcare sector rose to US$15.7 billion in 2017, boosted by Chinese drug r&d company WuXi Biologics’ debut on the Hong Kong Stock Exchange in June, which raised more than US$580 million. In 2018, it forecasts healthcare IPOs to become even more active, rising to US$22.3 billion globally.

“We’re seeing a lot of biotechs get to the point where they need more capital for R&D and they’re debating whether to raise capital through an IPO or just sell the business now to take advantage of all-time high valuations,” said Tom Rice, a Baker McKenzie securities partner based in New York. “As a result, we’ve seen a resurgence over the last year or so of dual-track IPO sale processes seeking to maximise value.”

Healthtech companies are also likely to pursue IPOs to raise capital for R&D and to manufacture and open up new distribution channels for their products.

“The healthcare IPO market is beginning to gain surer footing as IPO valuations become more competitive with m&a,” said Ashok Lalwani, head of Baker McKenzie’s international capital markets practice in Asia Pacific. “As IPO valuations rise, we should start to see more of a trend towards companies using IPOs as an exit route as opposed to a trade sale.”

Following a peak in deal activity in 2018, the Baker McKenzie’s Global Transactions Forecast, developed in association with Oxford Economics, forecasts that healthcare m&a and IPO transactions will decline in 2019 in line with a larger, worldwide trend of cooling deal activity in developed markets. “As interest rates rise, global trade and investment growth slows, and equity prices correct, we forecast healthcare m&a to drop modestly to US$414 billion in 2019, and further to US$368 billion in 2020,” it said.

After reaching a five-year high of US$22.3 billion in 2018, IPOs in the healthcare sector are expected to drop slightly to US$21.4 billion in 2019 before declining further to US$17.7 billion in 2020.

Posted on: 11/01/2018 UTC+08:00


News

Shares in orthopaedic specialists Asian Healthcare Specialists (AHS) shot up 52% at the open on their Catalist debut today.
Private equity firm Permira’s A$690 million (US$536 million) five-year leveraged buyout loan to help it acquire EQT’s stake in I-MED Radiology Network, Australia’s largest radiology company, has been flexed down.
Joanne Hannah has resigned as chief executive of Total Face Group, the first medical aesthetics company to list on the ASX, effective 1 May.
Lianluo Smart, which develops medical devices and wearable sleep respiratory products, has signed a strategic cooperation agreement with Meinian Onehealth Healthcare, the second largest healthcare provider in China.
After a choppy day of trading that saw shares in HKE Holdings, a Singapore-based contractor specialising in the medical and healthcare sectors, rise as much as 10%, they closed up 1.82% on their debut yesterday.
Summerset Group, New Zealand’s third-largest listed retirement village operator, has purchased land to build a retirement village in the suburb of Te Awa. The 9-ha property will be Summerset’s fourth in Hawke’s Bay. It already has villages in Havelock North, Hastings and Taradale.
Metlifecare, New Zealand’s second-largest listed retirement village operator, has said that its purchase of a 5.3 hectare waterfront site at Orion Point in Hobsonville, West Auckland, is now unconditional. The deal was announced at the end of October last year.
Hong Kong care home operator Pine Care Group has signed a management agreement with Zhejiang Yada Real Estate to operate and manage the Wuzhen Graceland Day Care Centre in Wuzhen, Zhejiang. Financial terms have not been disclosed.



Analysis

In Vietnam, population and GDP growth have encouraged the country to think beyond technology in providing more health for more people.
Focused initiatives drive down medical inflation by more than 50 percentage points, according to a new report from Aon Asia Healthcare.
The Japanese healthcare system is a shining example of strength and resilience. At an average lifespan of 84 years, the Japanese society is not only the healthiest but also the "oldest" in the world. However, the challenges presented by an ageing population pose serious threats to the sustainability of the Japanese health system.
Susann Roth, senior social development specialist, Asian Development Bank, explains how investing in energy makes people healthier.
CFO Luke Chen’s reticence on the Q3 earnings call on Friday now makes sense. Jack Ma’s Yunfeng Capital and Alibaba Investment will buy out iKang Healthcare Group, China’s largest private preventive healthcare services provider, for around US$1.4 billion.
Following news that Malaysian sovereign wealth fund Khazanah Nasional will acquire Prince Court Medical Centre (PCMC) from Petronas, IHH Healthcare, Asia’s largest healthcare company, has signed an agreement with Khazanah to look after the day-to-day running of the medical centre.
Malaysian-based primary healthcare provider Qualitas Medical Group is due to push the button on its S$150 million (US$114 million) IPO in Singapore next week. It will be the first mainboard healthcare listing since IHH Healthcare floated in Kuala Lumpur and Singapore in July 2012.
Sumit Sharma, head of health & life sciences, Asia Pacific, at Oliver Wyman, and Matt Zafra, engagement manager, health & life sciences, Oliver Wyman, look at the four themes that are going to dominate healthcare this year.
my images

Podcasts

Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices